Evans JM, Ogston SA, Emslie-Stnith A, Morris AD: Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin
Explore our newest blog to learn about our position on GLP-1 tapering here
It is also used to treat symptoms of depression, as it can improve your mood
Who do you think will lead the next breakthrough
has received consulting fees on behalf of Newcastle University from 89bio, Akero, Alimentiv, AstraZeneca, Axcella, Boehringer Ingelheim, Bristol Myers Squibb, Galmed, Genentech, Genfit, Gilead, GlaxoSmithKline, Hanmi, HistoIndex, Intercept, Inventiva, Ionis, IQVIA, Janssen, Madrigal, Medpace, Merck, NGMBio, Novartis, Novo Nordisk, PathAI, Pfizer, Pharmanest, Poxel, Prosciento, Resolution Therapeutics, Ridgeline Therapeutics, Roche, RTI, Shionogi and Terns Pharmaceuticals